Artículos del autor

solaci

Day 1

ESTUDO BIOSOLVE II: Estudo first-in-man demonstra melhores resultados com segunda geração de stent metálico eluidor de sirolimus bioabsorvível (DREAMS 2G) em comparação com BIOSOLVE...

Michael Haude
solaci -
Day 1

ABSORB II: Seguimento de 2 anos não demonstrou superioridade do scaffold bioabsorvível eluidor de everolimus vs stent metálico eluidor everolimus em pacientes com doença...

Bernard R. Chevalier
solaci -
Structural heart disease

TAVI in patients older than 90: similar outcomes to those obtained in younger patients

Original title: Comparison of Outcomes of Transcathether Aortic Valve Implantation in Patients ≥90 Years Versus <90 Years. Reference:...
solaci -
Coronary disease

Polymer Free Drug Coated Stent in High Bleeding Risk Patients with Only One Month DAPT

Original Title: Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk Reference: Philip Urban et al. N...
solaci -
N1 Revista de Cardiología Invasiva - Selección Marzo 2015

Procedimientos percutáneos combinados en defectos estructurales y congénitos

Francisco Chamié, Daniel Chamié, Luiz Carlos do Nascimento Simões, Renata Mat
solaci -
Drug-eluting stents

OPTIDUAL: Dual Antiaggregation Not Beneficial after 12 Months.

Extending dual antiaggregation therapy (DAT) from 12 to 48 months appears not to offer extra protection after...
solaci -
Highlights

Meta-analysis of prolonged DAT after DES

Extending the antiaggregation therapy over a year reduces adverse events in patients with a history of AMI,...
solaci -
Highlights

FAME at 5 years: FFR Should Guide All Multivessel PCIs

Though the benefit of FFR (fractional flow reserve) over angiography is statistically important only over the first...
solaci -